Device Firms Weigh Pros And Cons Of FDA-CMS Parallel Review
This article was originally published in The Gray Sheet
Executive Summary
As FDA and CMS edge closer to a joint program for pre-market review and reimbursement decision-making, device and diagnostic firms are expressing wariness about participating.
You may also be interested in...
Bringing Private Payers To The Regulatory Table: FDA Reaches Out To Insurers
The agency's device center put out a request to health insurers to make themselves available to participate in FDA pre-submission meetings so that device firms, particularly start-ups, can better understand data expectations for coverage while companies are still designing studies to support FDA approval.
Calling All Innovators: FDA And CMS Seek Candidates For Parallel Review Pilot
FDA and CMS are seeking device companies with innovative technologies to participate in the first test of "parallel," or simultaneous, pre-market approval and Medicare coverage reviews.
Calling All Innovators: FDA And CMS Seek Candidates For Parallel Review Pilot
FDA and CMS are seeking device companies with innovative technologies to participate in the first test of "parallel," or simultaneous, pre-market approval and Medicare coverage reviews.